Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12- but not B7-1-transfected tumor cells

International Immunology

Volumn 9, Issue 9, 1997, Pages 1259-1269

  Fallarino, Franceses ^a   Ashikari, Andrew ^a   Boon, Thierry ^b   Gajewski, Thomas F ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Co stimulation; IL 12; T lymphocytes; Tumor rejection; Vaccine

Indexed keywords

B7 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 12;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENETIC TRANSFECTION; IMMUNOGENICITY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TUMOR REGRESSION;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL DIVISION; DRUG SYNERGISM; EPITOPES; FEMALE; GRAFT REJECTION; IMMUNOCONJUGATES; IMMUNOPHENOTYPING; INTERLEUKIN-12; LEUKEMIA L1210; LIGANDS; MAST-CELL SARCOMA; MICE; MICE, INBRED DBA; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

EID: 0030763676     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/9.9.1259     Document Type: Article

References (35)

1. Van den Eynde, B., Lethe, B., Van Pel, A., De Plaen, E. and Boon, T. 1991. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J. Exp. Med. 173:1373.
2. Van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A. and Boon, T. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643.
3. De Plaen, E., Arden, K., Traversari, C., Gaforio, J. J., Szikora, J., De Smet, C., Brasseur, F., Van der Bruggen, P., Lethe, B., Lurquin, C., Brasseur, R., Chomez, P., De Backer, O., Cavenee, W. and Boon, T. 1994. Structure, chromosomal location, and expression of 12 genes of the MAGE family. Immunogenetics 40:360.
4. Boon, T., Cerottini, J., Van den Eynde, B., Van der Bruggen, P. and Van Pel, A. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol 12:337.
5. Brichard, V. G., Warnier, G., Van Pel, A., Morlighem, G., Lucas, S. and Boon, T. 1995. Individual differences in the orientation of the cytolytic T cell responses against mouse tumor P815. Eur. J. Immunol. 25:664.
6. Van Pel, A., Van der Bruggen, P., Coulie, P. G., Brichard, V. G., Lethe, B., Van den Eynde, B., Uyttenhove, C., Renauld, J.-C. and Boon, T. 1995. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol. Rev. 145:229.
7. Uyttenhove, C., Van Snick, J. and Boon, T. 1980. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice. J. Exp. Med. 152:1175.
8. - transplantation antigen P198: a point mutation generates a new antigenic peptide. J. Exp Med. 172:35.
9. - antigen with a cytolytic T cell stimulation assay. Immunogenetics 26:178.
10. - mutation. Proc. Natl Acad. Sci. USA 85:2274.
11. Van Pel, A., De Plaen, E. and Boon, T. 1985. Selection of a highly transfectable variant from mouse mastocytoma P815. Somat. Cell Mol. Genet. 11:467.
12. + T cells by B7-transfected melanoma cells. Science 259:368.
13. Chen, L., McGowan, P., Ashe, S., Johnston, J., Li, Y., Hellstrom, I. and Hellstrom, K. E. 1994. Tumor immunogenicity determines the effect of B7 co-stimulation on T cell-mediated tumor immunity. J. Exp. Med. 179:523.
14. Townsend, S. E., Su, F. W., Atherton, J. M. and Allison, J. P. 1994. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res. 54:6477.
15. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med. 181:619.
16. Chen, L., Linsley, P. S. and Hellstrom, K. E. 1993. Costimulation of T cells for tumor immunity. Immunol. Today 14:483.
17. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D. and Mulligan, R. C. 1993. Vaccination with irradiated tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90:3539.
18. Colombo, M. P. and Forni, G.1994. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol. Today 15:48.
19. Golumbek, P. T, Lazenby, A. J., Levitsky, H. I., Jaffee, L. M., Karasuyama, H., Baker, M. and Pardoll, D. M. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713.
20. Richter, G., Kruger-Krasagakes, S., Hein, G., Huls, G., Schmitt, E., Diamantstein, T and Blankenstein, T1993. Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res. 53:4134.
21. Laning, J., Kawasaki, H., Tanaka, E., Luo, Y. and Dorf. M. E. 1994. Inhibition of in vivo tumor growth by the β chemokine, TCA3. J. Immunol. 153:4625.
22. Zitvogel, L., Tahara, H., Robbins, P. D., Storkus, W. J., Clarke, M. R., Nalesnik, M. A. and Lotze, M. T. 1995. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J. Immunol. 155:1393.
23. Gajewski, T. F., Uyttenhove, C., Fallarino, F. and Boon, T. 1996. Tumor rejection requires a CTLA-4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J. Immunol. 156:2909.
24. Fallarino, F., Uyttenhove, C., Boon, T. and Gajewski, T. F. 1996. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J. Immunol. 156:1095.
25. Gajewski, T. F., Renauld, J.-C., Van Pel, A. and Boon, T. 1995. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine anti-tumor cytolytic T lymphocytes in vitro. J. Immunol. 154:5637.
26. Schoenhaut, D. S., Chua, A. O., Wolitzky, A. G., Quinn, P. M., Dwyer, C. M., McComas, W., Familletti, P. C., Gately, M. K. and Gubler, U. 1992. Cloning and expression of murine IL-12. J. Immunol. 148:3433.
27. Lancki, D. W., Weiss, A. and Fitch, F. W. 1987. Requirements for triggering of lysis by cytolytic T lymphocyte clones. J. Immunol. 138:3646.
28. Trinchieri, G, 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13:251.
29. Voest, E. E., Kenyon, B. M., O'Reilly, M. S., Truitt, G., D'Amato, R. J. and Folkman, J. 1995. Inhibition of angiogenesis in vivo by interleukin 12. J. Natl Cancer Inst. 87:581.
30. Tahara, H., Zitvogel, L., Storkus, W. J., Zeh, H. J., McKinney, T. G., Schreiber, R. D., Gubler, U., Robbins, P. D. and Lotze, M. T. 1995. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol. 154:6466.
31. Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F. and Gately, M. K. 1993. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178:1223.
32. Brunda, M. J., Luistro, L., Hendrzak, J. A., Fountoulakis, M., Garotta, G. and Gately, M. K. 1995. Role of IFN-γ in mediating the antitumor efficacy of interleukin-12. J. Immunother. 17:71.
33. Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D. and Levitsky, H. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961.
34. Huang, A. Y. C., Bruce, A. T., Pardoll, D. M. and Levitsky, H. I. 1996. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J. Exp. Med. 183:769.
35. Kubin, M., Kamoun, M. and Trinchieri, G. 1994. Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J. Exp. Med. 180:211.